Volumizing Hyaluronic Acid Filler for Midface Volume Deficit: 2‐Year Results from a Pivotal Single‐Blind Randomized Controlled Study

Diane Murphy,Derek H. Jones
DOI: https://doi.org/10.1111/dsu.12343
2013-11-01
Dermatologic Surgery
Abstract:BACKGROUND Hyaluronic acid (HA) gels are commonly used to correct age‐related midface volume deficit (MVD), yet the Food and Drug Administration has not specifically approved them for this purpose. OBJECTIVE To study the safety and effectiveness of a new 20‐mg/mL HA gel (VYC‐20L) specifically formulated and optimized for mid‐face volumizing. METHODS AND MATERIALS A multicenter, single‐blind, controlled study randomized 235 subjects aged 35 to 65 with MVD to a treatment group and 47 to a no‐treatment control group. Responders were defined as subjects who achieved improvement of 1 point or more on the validated 6‐point Mid‐Face Volume Deficit Scale (MFVDS) at 6 months as rated live by two blinded independent evaluators. The primary endpoint required a 70% or greater treatment group response and a statistically significant difference (p < .001) between the treatment and control group responder rates. RESULTS The primary endpoint was met, with 85.6% of the treatment group improving by 1 point or more on the MFVDS at month 6 and a statistically significant difference (p < .001) between the treatment and control group responder rates. Subjects tolerated VYC‐20L well, with no unanticipated adverse device effects. Nearly half of subjects maintained correction for 24 months. CONCLUSION VYC‐20L is safe and effective for age‐related MVD, with correction lasting up to 2 years.
Medicine
What problem does this paper attempt to address?